

## **MTS HIGH-END LITHOTRIPTOR LITHOGOLD380 RECEIVES CE-CERTIFICATION**

**MTS Europe GmbH, Konstanz, Germany, achieves CE certification of its high-end lithotripter lithogold380. The device approval puts an efficient and tissue-protective therapy for kidney stones within reach of European patients.**

MTS situated in Konstanz, Germany, successfully achieved certification of its high-end lithotripter according to EU standards beginning of 2011. The device approval puts the efficient and tissue-protective therapy for kidney stones, other urological as well as orthopaedic indications within reach of European patients.

lithogold380 is characterised by a focal area of 20 x 100 mm, a penetration depth of 165 mm as well as a maximum treatment pressure of 36,6 MPa. It is proven that the huge therapeutic area reduces the re-treatment rate to less than 7%. Its limited treatment pressure assures a tissue-protective therapy requesting less anaesthesia.

In 2006 MTS' shockwave lithotripter lithogold380 already received FDA approval and has obtained an excellent reputation in the U.S. with respect to efficacy and practically no adverse effects.

MTS Europe GmbH, a company of TRT LLC, USA, specializes in the development and manufacture of extracorporeal shockwave therapy systems, which are used in orthopaedics, traumatology, wound management and urology worldwide. The group is leading in the field of medical shockwave research and becoming market leader in non-invasive therapy of chronic wounds.

Konstanz, 3.2.2011sd